دورية أكاديمية
B Cell Orchestration of Anti-tumor Immune Responses: A Matter of Cell Localization and Communication.
| العنوان: | B Cell Orchestration of Anti-tumor Immune Responses: A Matter of Cell Localization and Communication. |
|---|---|
| المؤلفون: | Kinker GS; Translational Immuno-oncology Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil., Vitiello GAF; Translational Immuno-oncology Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.; Department of Pathological Sciences, Londrina State University, Londrina, Brazil., Ferreira WAS; Translational Immuno-oncology Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.; Laboratory of Tissue Culture and Cytogenetics, Environment Section (SAMAM), Evandro Chagas Institute, Ananindeua, Brazil., Chaves AS; Translational Immuno-oncology Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil., Cordeiro de Lima VC; Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, Brazil.; Oncologia D'Or São Paulo, Rede D'or, São Paulo, Brazil., Medina TDS; Translational Immuno-oncology Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.; National Institute of Science and Technology in Oncogenomics and Therapeutic Innovation, São Paulo, Brazil. |
| المصدر: | Frontiers in cell and developmental biology [Front Cell Dev Biol] 2021 Jun 07; Vol. 9, pp. 678127. Date of Electronic Publication: 2021 Jun 07 (Print Publication: 2021). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101630250 Publication Model: eCollection Cited Medium: Print ISSN: 2296-634X (Print) Linking ISSN: 2296634X NLM ISO Abbreviation: Front Cell Dev Biol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Media S.A., [2013]- |
| مستخلص: | The immune system plays a crucial role in cancer development either by fostering tumor growth or destroying tumor cells, which has open new avenues for cancer immunotherapy. It was only over the last decade that the role of B cells in controlling anti-tumor immune responses in the tumor milieu has begun to be appreciated. B and plasma cells can exert anti-tumor effects through antibody-dependent cell cytotoxicity (ADCC) and activation of the complement cascade, even though their effector functions extend beyond the classical humoral immunity. In tumor tissues, B cells can be found in lymphoid aggregates, known as tertiary lymphoid structures (TLSs), well-organized non-encapsulated structures composed of immune and stromal cells. These structures reflect a process of lymphoid neogenesis occurring in peripheral tissues upon long-lasting exposure to inflammatory signals. The TLS provides an area of intense B cell antigen presentation that can lead to optimal T cell activation and effector functions, as well as the generation of effector B cells, which can be further differentiated in either antibody-secreting plasma cells or memory B cells. Of clinical interest, the crosstalk between B cells and antigen-experienced and exhausted CD8 + T cells within mature TLS was recently associated with improved response to immune checkpoint blockade (ICB) in melanoma, sarcoma and lung cancer. Otherwise, B cells sparsely distributed in the tumor microenvironment or organized in immature TLSs were found to exert immune-regulatory functions, inhibiting anti-tumor immunity through the secretion of anti-inflammatory cytokines. Such phenotype might arise when B cells interact with malignant cells rather than T and dendritic cells. Differences in the spatial distribution likely underlie discrepancies between the role of B cells inferred from human samples or mouse models. Many fast-growing orthotopic tumors develop a malignant cell-rich bulk with reduced stroma and are devoid of TLSs, which highlights the importance of carefully selecting pre-clinical models. In summary, strategies that promote TLS formation in close proximity to tumor cells are likely to favor immunotherapy responses. Here, the cellular and molecular programs coordinating B cell development, activation and organization within TLSs will be reviewed, focusing on their translational relevance to cancer immunotherapy. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Kinker, Vitiello, Ferreira, Chaves, Cordeiro de Lima and Medina.) |
| References: | Am J Pathol. 2011 Jul;179(1):37-45. (PMID: 21703392) J Allergy Clin Immunol. 2010 Nov;126(5):898-907; quiz 908-9. (PMID: 21050940) J Clin Oncol. 2008 Sep 20;26(27):4410-7. (PMID: 18802153) Cancer Discov. 2016 Mar;6(3):256-69. (PMID: 26715642) J Clin Oncol. 2015 Apr 20;33(12):1325-33. (PMID: 25584002) Front Immunol. 2018 Sep 12;9:1952. (PMID: 30258435) Front Immunol. 2020 Aug 20;11:1884. (PMID: 32973780) Immunity. 2018 Oct 16;49(4):695-708.e4. (PMID: 30291027) Autoimmun Rev. 2012 Jul;11(9):670-7. (PMID: 22155204) J Transl Med. 2014 Jan 30;12:30. (PMID: 24475900) Nat Rev Immunol. 2020 May;20(5):294-307. (PMID: 31988391) Yakugaku Zasshi. 2013;133(4):419-25. (PMID: 23546586) Int Immunol. 1998 Oct;10(10):1563-72. (PMID: 9796923) Blood. 2006 May 15;107(10):3925-32. (PMID: 16418326) Nat Biotechnol. 2017 Oct 11;35(10):908-911. (PMID: 29020005) Int Immunol. 2001 Dec;13(12):1583-93. (PMID: 11717199) Mol Immunol. 2020 Mar;119:83-91. (PMID: 32001420) Sci Rep. 2020 Mar 20;10(1):5142. (PMID: 32198367) Cancer Immunol Res. 2017 Oct;5(10):898-907. (PMID: 28848053) Lancet Oncol. 2016 Dec;17(12):e542-e551. (PMID: 27924752) J Exp Med. 2014 Dec 15;211(13):2567-81. (PMID: 25403444) Nat Rev Cancer. 2019 Jun;19(6):307-325. (PMID: 31092904) Cancers (Basel). 2020 Sep 16;12(9):. (PMID: 32947928) J Immunother Cancer. 2021 Jan;9(1):. (PMID: 33452206) Autoimmunity. 2017 Feb;50(1):4-18. (PMID: 28166685) Cell. 2004 Jan 23;116(2):299-311. (PMID: 14744439) Nature. 2017 Nov 16;551(7680):340-345. (PMID: 29144460) J Surg Res. 2017 Jul;215:74-82. (PMID: 28688665) Clin Cancer Res. 2018 Dec 15;24(24):6125-6135. (PMID: 30049748) J Clin Pathol. 2016 May;69(5):422-30. (PMID: 26475777) Front Immunol. 2019 Dec 17;10:2965. (PMID: 31921205) Gastroenterology. 2017 Dec;153(6):1517-1530.e14. (PMID: 28865736) Clin Cancer Res. 2021 Mar 1;27(5):1278-1286. (PMID: 33277370) Int J Biochem Cell Biol. 2014 Dec;57:63-8. (PMID: 25450457) Immunity. 2016 Mar 15;44(3):683-697. (PMID: 26968426) Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230) BMC Biotechnol. 2007 Oct 18;7:70. (PMID: 17945015) J Immunother Cancer. 2016 Jul 19;4:40. (PMID: 27437104) J Exp Med. 2000 Aug 21;192(4):475-82. (PMID: 10952717) J Transl Med. 2020 May 28;18(1):214. (PMID: 32466781) Oral Oncol. 2016 Feb;53:27-35. (PMID: 26631955) J Immunol. 2013 Oct 15;191(8):4141-51. (PMID: 24043896) Nature. 2021 Mar;591(7850):464-470. (PMID: 33536615) Oncologist. 2017 Nov;22(11):1316-1324. (PMID: 28701569) Nature. 2020 Jan;577(7791):549-555. (PMID: 31942075) Clin Cancer Res. 2013 Nov 1;19(21):5994-6005. (PMID: 24056784) Nat Rev Nephrol. 2019 Jan;15(1):11-26. (PMID: 30443016) Nature. 2020 Jan;577(7791):556-560. (PMID: 31942077) Nat Commun. 2021 Apr 12;12(1):2186. (PMID: 33846305) Cell Mol Immunol. 2017 Aug;14(8):662-674. (PMID: 28626234) Br J Cancer. 2021 May;124(10):1680-1689. (PMID: 33723388) Nature. 2007 Mar 29;446(7135):547-51. (PMID: 17322904) J Clin Invest. 2017 Mar 1;127(3):772-779. (PMID: 28248202) Oncoimmunology. 2013 Jul 1;2(7):e25443. (PMID: 24073382) Oncotarget. 2014 Jul 15;5(13):4651-64. (PMID: 25026291) J Immunol. 2010 May 1;184(9):5344-51. (PMID: 20357253) J Dermatol Sci. 2019 Jan;93(1):2-7. (PMID: 30514664) J Immunol. 2014 Nov 15;193(10):4924-33. (PMID: 25305321) J Immunol. 2009 May 1;182(9):5439-45. (PMID: 19380791) Front Immunol. 2019 Mar 27;10:542. (PMID: 30972056) Oncotarget. 2015 Oct 20;6(32):33486-99. (PMID: 26378021) Nat Genet. 2019 Mar;51(3):560-567. (PMID: 30742113) Heliyon. 2016 Aug 16;2(8):e00143. (PMID: 27579449) Blood. 2011 Jan 13;117(2):530-41. (PMID: 20962324) Sci Rep. 2015 Jul 20;5:12255. (PMID: 26193241) Am J Clin Pathol. 2006 Mar;125(3):451-8. (PMID: 16613351) Signal Transduct Target Ther. 2018 Sep 28;3:26. (PMID: 30275987) Eur J Immunol. 2015 Apr;45(4):999-1009. (PMID: 25545618) J Transl Med. 2014 Nov 11;12:304. (PMID: 25381811) J Immunol. 2009 May 1;182(9):5789-99. (PMID: 19380827) Cancer Immunol Immunother. 2000 Jan;48(10):541-9. (PMID: 10630306) Nature. 2015 May 7;521(7550):94-8. (PMID: 25924065) Afr Health Sci. 2020 Sep;20(3):1264-1272. (PMID: 33402974) Cancer Immunol Immunother. 2011 Dec;60(12):1729-38. (PMID: 21779876) J Leukoc Biol. 2003 Mar;73(3):323-32. (PMID: 12629145) J Allergy Clin Immunol. 2013 Apr;131(4):959-71. (PMID: 23465663) Arch Med Sci. 2019 Sep;15(5):1176-1183. (PMID: 31572462) Nat Commun. 2017 Sep 28;8(1):719. (PMID: 28959012) Immunity. 2011 Dec 23;35(6):986-96. (PMID: 22177922) Immunol Rev. 2010 Sep;237(1):22-42. (PMID: 20727027) Oncoimmunology. 2015 Sep 11;5(4):e1085147. (PMID: 27141376) Cancer Res. 2003 Jun 15;63(12):3275-80. (PMID: 12810659) Cancer Res. 2012 Mar 1;72(5):1070-80. (PMID: 22266112) Nat Rev Immunol. 2014 Jul;14(7):447-62. (PMID: 24948366) PLoS One. 2011 Apr 29;6(4):e19330. (PMID: 21559411) J Immunother Cancer. 2018 Dec 10;6(1):145. (PMID: 30526680) Nat Med. 2014 Jun;20(6):633-41. (PMID: 24743305) Annu Rev Immunol. 2006;24:541-70. (PMID: 16551259) Front Immunol. 2021 Mar 08;12:626776. (PMID: 33763071) J Immunol. 2003 Jun 1;170(11):5475-82. (PMID: 12759424) Oncoimmunology. 2015 Jun 1;4(12):e1051922. (PMID: 26587322) Clin Cancer Res. 2017 Jan 1;23(1):250-262. (PMID: 27354470) Clin Cancer Res. 2020 Jul 15;26(14):3578-3588. (PMID: 32273276) Cell Rep. 2019 Nov 12;29(7):1878-1892.e7. (PMID: 31722204) J Immunol. 2004 Feb 1;172(3):1501-7. (PMID: 14734727) Int J Cancer. 2014 May 1;134(9):2126-35. (PMID: 24154855) Immunity. 2014 Dec 18;41(6):1040-51. (PMID: 25484301) Genes Dev. 2004 Feb 15;18(4):411-22. (PMID: 15004008) Curr Opin Immunol. 2018 Apr;51:46-54. (PMID: 29477969) BMC Med. 2016 May 05;14:73. (PMID: 27151159) Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13866-71. (PMID: 11698646) J Ovarian Res. 2016 Apr 06;9:21. (PMID: 27048364) J Immunol. 2005 May 1;174(9):5233-42. (PMID: 15843519) Cancer Discov. 2016 May;6(5):477-8. (PMID: 27138562) Diabetes. 2012 Nov;61(11):2893-905. (PMID: 22829452) J Immunol. 2011 Nov 15;187(10):5183-95. (PMID: 22003198) J Autoimmun. 2015 May;59:53-60. (PMID: 25753821) Cancer Immunol Res. 2014 Jul;2(7):616-31. (PMID: 24942756) J Immunol. 2018 Jul 1;201(1):278-295. (PMID: 29752311) Nat Immunol. 2009 Nov;10(11):1193-9. (PMID: 19783990) Adv Exp Med Biol. 2020;1254:87-103. (PMID: 32323272) Sci Rep. 2019 Dec 27;9(1):19997. (PMID: 31882709) Medicine (Baltimore). 2018 May;97(19):e0710. (PMID: 29742730) Oncotarget. 2017 Dec 7;9(19):14803-14814. (PMID: 29599908) Br J Cancer. 2015 Mar 17;112(6):1067-75. (PMID: 25668006) Nat Rev Immunol. 2020 Aug;20(8):483-497. (PMID: 32024984) J Immunol. 2008 Feb 1;180(3):1362-72. (PMID: 18209030) Breast Cancer Res Treat. 2012 Apr;132(2):545-53. (PMID: 21671016) Cancer Lett. 2014 Dec 28;355(2):264-72. (PMID: 25301451) Cancer Discov. 2016 May;6(5):546-59. (PMID: 26928313) Nature. 2012 Nov 8;491(7423):264-8. (PMID: 23064231) Biomark Res. 2020 Aug 26;8:34. (PMID: 32864131) Cell Mol Immunol. 2020 Aug;17(8):807-821. (PMID: 32612154) Cancer Res. 2013 Apr 15;73(8):2468-79. (PMID: 23384943) Clin Cancer Res. 2016 Jun 15;22(12):3005-15. (PMID: 26763251) J Hepatol. 2019 Jan;70(1):58-65. (PMID: 30213589) Oncoimmunology. 2018 Feb 20;7(4):e1413520. (PMID: 29632731) J Immunol. 2017 Nov 15;199(10):3387-3394. (PMID: 29109178) Cell. 2019 Apr 18;177(3):524-540. (PMID: 31002794) Arch Immunol Ther Exp (Warsz). 2008 Mar-Apr;56(2):77-83. (PMID: 18373241) Cancer Res. 2012 Aug 15;72(16):3997-4007. (PMID: 22850419) Annu Rev Immunol. 2015;33:715-45. (PMID: 25861980) Tumour Biol. 2016 May;37(5):6581-8. (PMID: 26638169) Cancer Res. 2011 May 15;71(10):3505-15. (PMID: 21444674) Clin Exp Metastasis. 2016 Oct;33(7):727-39. (PMID: 27449756) JCI Insight. 2019 Aug 13;5:. (PMID: 31408436) Cancer Immunol Res. 2015 Oct;3(10):1148-1157. (PMID: 26014098) Anticancer Res. 2016 Oct;36(10):5339-5345. (PMID: 27798897) J Immunol. 2013 Mar 15;190(6):2575-84. (PMID: 23408836) Br J Haematol. 2020 Dec;191(5):e116-e120. (PMID: 33460063) Nat Med. 2014 Nov;20(11):1334-9. (PMID: 25326801) Methods Mol Biol. 2021;2270:235-261. (PMID: 33479902) Nature. 2020 Jan;577(7791):561-565. (PMID: 31942071) J Mol Med (Berl). 2010 Nov;88(11):1169-80. (PMID: 20798913) Eur J Cancer. 2021 May;148:181-189. (PMID: 33743486) PLoS One. 2018 Jul 5;13(7):e0199034. (PMID: 29975708) Ann Oncol. 2018 Aug 1;29(8):1853-1860. (PMID: 29982279) Nat Commun. 2017 Sep 19;8(1):607. (PMID: 28928360) J Immunol. 2005 May 1;174(9):5720-8. (PMID: 15843574) J Immunother Cancer. 2019 Oct 29;7(1):279. (PMID: 31665076) Nat Rev Cancer. 2020 Apr;20(4):218-232. (PMID: 32024970) J Exp Med. 2016 May 2;213(5):715-32. (PMID: 27069112) Nat Commun. 2018 Jan 17;9(1):251. (PMID: 29343683) Front Immunol. 2017 Jul 21;8:830. (PMID: 28785261) Sci Rep. 2019 Sep 11;9(1):13083. (PMID: 31511630) Clin Cancer Res. 2020 Oct 1;26(19):5129-5139. (PMID: 32591464) Nat Rev Cancer. 2019 Mar;19(3):151-161. (PMID: 30723290) J Immunol. 2014 Apr 15;192(8):3626-36. (PMID: 24616478) Cancer Res. 2018 Mar 1;78(5):1308-1320. (PMID: 29279354) Immunity. 2006 Jul;25(1):31-41. (PMID: 16860755) Science. 2015 Apr 3;348(6230):69-74. (PMID: 25838375) Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10468-73. (PMID: 22689978) J Immunol. 2002 Aug 15;169(4):1829-36. (PMID: 12165506) Nat Rev Immunol. 2009 Nov;9(11):767-77. (PMID: 19855403) Oncoimmunology. 2017 Dec 18;7(2):e1378844. (PMID: 29416939) PLoS One. 2013 May 29;8(5):e64159. (PMID: 23734190) Breast Cancer Res Treat. 2018 Sep;171(2):273-282. (PMID: 29858752) Immunity. 2011 May 27;34(5):703-14. (PMID: 21530328) Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13490-13497. (PMID: 31213547) Front Immunol. 2017 Mar 23;8:319. (PMID: 28386257) Nat Commun. 2015 Jan 22;6:5997. (PMID: 25609381) Curr Top Microbiol Immunol. 2005;290:1-14. (PMID: 16480036) Nature. 2010 Mar 11;464(7286):302-5. (PMID: 20220849) Cancer Lett. 2013 Jun 10;333(2):222-8. (PMID: 23370224) J Exp Med. 2012 Apr 9;209(4):729-40. (PMID: 22430492) Clin Cancer Res. 2020 Aug 15;26(16):4381-4389. (PMID: 32269054) Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11019-24. (PMID: 8855301) Cold Spring Harb Perspect Biol. 2012 Dec 01;4(12):. (PMID: 23209149) Immunity. 2016 Apr 19;44(4):913-923. (PMID: 27096320) Nat Commun. 2020 Jul 8;11(1):3412. (PMID: 32641742) Immunol Cell Biol. 2015 May-Jun;93(5):486-99. (PMID: 25533286) Cancer Immunol Immunother. 2019 Nov;68(11):1733-1745. (PMID: 31598757) Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44. (PMID: 24484236) J Immunol. 2003 Feb 1;170(3):1191-6. (PMID: 12538675) Nat Immunol. 2004 Jul;5(7):713-20. (PMID: 15184895) Cent Eur J Immunol. 2015;40(2):263-5. (PMID: 26557042) Nat Immunol. 2002 Oct;3(10):944-50. (PMID: 12244307) Nature. 2015 May 7;521(7550):99-104. (PMID: 25924063) Cancer Discov. 2016 Mar;6(3):247-55. (PMID: 26715643) Histopathology. 2017 Aug;71(2):258-268. (PMID: 28326600) Mol Cell. 2000 Feb;5(2):343-53. (PMID: 10882075) Int J Mol Sci. 2018 Jun 30;19(7):. (PMID: 29966360) Blood. 2013 Jul 4;122(1):9-18. (PMID: 23678003) J Allergy Clin Immunol. 2013 Apr;131(4):1204-12. (PMID: 23453135) Oncoimmunology. 2018 Nov 2;8(1):e1512458. (PMID: 30546950) Semin Immunopathol. 2019 Mar;41(2):225-237. (PMID: 30361803) PLoS One. 2010 Sep 27;5(9):e13016. (PMID: 20885961) Nat Immunol. 2017 Nov;18(11):1207-1217. (PMID: 28892469) Nat Methods. 2019 Oct;16(10):987-990. (PMID: 31501547) Clin Exp Immunol. 2020 Feb;199(2):172-181. (PMID: 31652350) Clin Cancer Res. 2012 Jun 15;18(12):3281-92. (PMID: 22553348) Br J Cancer. 2015 May 26;112(11):1782-90. (PMID: 25942397) Int Immunopharmacol. 2020 Jan;78:106111. (PMID: 31881524) |
| فهرسة مساهمة: | Keywords: B lymphocytes; T lymphocytes; anti-tumor responses; germinal center; pro-tumor responses; tertiary lymphoid structures; tumor |
| تواريخ الأحداث: | Date Created: 20210624 Latest Revision: 20240402 |
| رمز التحديث: | 20240402 |
| مُعرف محوري في PubMed: | PMC8215448 |
| DOI: | 10.3389/fcell.2021.678127 |
| PMID: | 34164398 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2296-634X |
|---|---|
| DOI: | 10.3389/fcell.2021.678127 |